Comparative Pharmacology
Head-to-head clinical analysis: NESINA versus SAXAGLIPTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NESINA versus SAXAGLIPTIN.
NESINA vs SAXAGLIPTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibitor of dipeptidyl peptidase-4 (DPP-4), preventing inactivation of incretin hormones (GLP-1, GIP), thereby increasing insulin secretion and decreasing glucagon release in a glucose-dependent manner.
Saxagliptin is a selective, reversible inhibitor of dipeptidyl peptidase-4 (DPP-4), which prolongs the action of incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby enhancing glucose-dependent insulin secretion and suppressing glucagon release.
25 mg orally once daily.
2.5 mg or 5 mg orally once daily irrespective of meals.
None Documented
None Documented
Terminal elimination half-life: 12.4–26.1 hours (mean ~21 hours); supports once-daily dosing
Clinical Note
moderateSaxagliptin + Gatifloxacin
"Saxagliptin may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateSaxagliptin + Rosoxacin
"Saxagliptin may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateSaxagliptin + Levofloxacin
"Saxagliptin may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateSaxagliptin + Trovafloxacin
"Saxagliptin may increase the hypoglycemic activities of Trovafloxacin."
Terminal half-life: 2.5 hours; accounts for DPP-4 inhibition duration despite rapid clearance.
Renal: 87% (75% as unchanged drug, 12% as inactive metabolites); Fecal: <1%
Renal (75% as unchanged drug and metabolites; 25% as unchanged drug in urine) and fecal (22% as metabolites).
Category C
Category A/B
DPP-4 Inhibitor
DPP-4 Inhibitor